Therapeutic formulations

Details Therapeutic formulations Therapeutic formulations

2006-08-15

2006-08-15

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S365000, C536S103000

Reexamination Certificate

active

07091193

ABSTRACT:
Formulations comprising one or more epothilones together with a pharmaceutically acceptable carrier, in particular such pharmaceutical compositions suitable for oral administration of an epothilone.

REFERENCES:
patent: 6194181 (2001-02-01), Hofmann et al.
patent: 6380227 (2002-04-01), Mutz
patent: 6380395 (2002-04-01), Vite et al.
patent: 6683100 (2004-01-01), van Hoogevest
patent: 2005/0148543 (2005-07-01), Sherrill et al.
patent: WO 99/39694 (1999-08-01), None
patent: WO 99/42602 (1999-09-01), None
patent: WO 02/066033 (2002-08-01), None
patent: WO 02/066038 (2002-08-01), None
Stephen R.D. Johnston, “Exemestane,”Current Opinion in Oncologic, Endocrine,&Metabolic Investiogatioanal Drugs(1999) 1(5): 560-572; Abstract.
Chou et al.,Proc. Natl. Acad. Sci. USA, 1998, 95, 15798-15802, “Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel”.
Demario et al.,J. Clinical Oncology, 1998, 16 (7), 2557-2567, “Oral Chemotherapy: Rationale and Future Directions”.
Sigma-Aldrich on-line catalog, product P1754, “TWEEN 80” (polyoxyethylenesorbitan monooleate), accessed Oct. 14, 2005.

Affiliated with

Also associated with

Rating

Therapeutic formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3709620